HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Huff, M. W. Articles by Sawyez, C. G. Search for Related Content PubMed PubMed Citation Articles by Huff, M. W. Articles by Sawyez, C. G. Social Bookmarking                      What's this?

Journal of Lipid Research, Vol 38, 1318-1333, Copyright © 1997 by Lipid Research, Inc.

ARTICLES

Uptake of hypertriglyceridemic very low density lipoproteins and their remnants by HepG2 cells: the role of lipoprotein lipase, hepatic triglyceride lipase, and cell surface proteoglycans

MW Huff, DB Miller, BM Wolfe, PW Connelly and CG Sawyez
Department of Medicine and the Robarts Research Institute, The University of Western Ontario, London, Canada.

Hypertriglyceridemic very low density lipoproteins (HTG-VLDL, S(f) 60- 400) are not taken up by HepG2 cells. However, addition of bovine milk lipoprotein lipase (LPL) at physiological concentrations markedly stimulates uptake. In the present study, we determined whether: a) LPL catalytic activity is required for uptake, b) LPL functions as a ligand, and c) cell surface hepatic triglyceride lipase (HL) and/or proteoglycans are involved. Incubation of HepG2 cells with HTG-VLDL plus LPL (8 ng/ml) increased cellular cholesteryl ester (CE) 3.5-fold and triglyceride (TG) 6-fold. Heat-inactivation of LPL abolished the effect. Addition of tetrahydrolipstatin (THL, an LPL active-site inhibitor) to HTG-VLDL + LPL, inhibited the cellular increase in both CE and TG by greater than 90%. Co-incubation of HTG-VLDL + LPL with heparin, heparinase, or heparitinase, blocked CE accumulation by 70%, 48%, and 95%, respectively, but had no effect on the increase in cellular TG. Pre-treatment of cells with 1 mM 4-methylumbelliferyl-beta- D-xyloside, (beta-xyloside) to reduce cell surface proteoglycans inhibited the increase in CE induced by HTG-VLDL + LPL by 78%. HTG-VLDL remnants, prepared in vitro and isolated free of LPL activity, stimulated HepG2 cell CE 2.8-fold in the absence of added LPL, a process inhibited with THL by 66%. Addition of LPL (8 ng/ml) to remnants did not further enhance CE accumulation. HepG2 cell HL activity, released by heparin, was inhibited 95% by THL. The amount of HL activity and immunoreactive mass, released by heparin, was reduced 50-60% in beta-xyloside-treated cells. These results indicate that physiological concentrations of LPL promote HepG2 cell uptake of HTG- VLDL primarily due to remnant formation and that LPL does not play a major role as a ligand. HL activity and cell surface proteoglycans significantly enhance the subsequent uptake of VLDL remnants.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				L. Hu, C. C. van der Hoogt, S. M. S. Espirito Santo, R. Out, K. E. Kypreos, B. J. M. van Vlijmen, T. J. C. Van Berkel, J. A. Romijn, L. M. Havekes, K. W. van Dijk, et al. The hepatic uptake of VLDL in lrp-ldlr-/-vldlr-/- mice is regulated by LPL activity and involves proteoglycans and SR-BI J. Lipid Res., July 1, 2008; 49(7): 1553 - 1561. [Abstract] [Full Text] [PDF]

				A. Kawakami, A. Tanaka, T. Chiba, K. Nakajima, K. Shimokado, and M. Yoshida Remnant Lipoprotein-Induced Smooth Muscle Cell Proliferation Involves Epidermal Growth Factor Receptor Transactivation Circulation, November 25, 2003; 108(21): 2679 - 2688. [Abstract] [Full Text] [PDF]

				J. E. Hokanson, M. I. Kamboh, S. Scarboro, R. H. Eckel, and R. F. Hamman Effects of the Hepatic Lipase Gene and Physical Activity on Coronary Heart Disease Risk Am. J. Epidemiol., November 1, 2003; 158(9): 836 - 843. [Abstract] [Full Text] [PDF]

				S. S. Deeb, A. Zambon, M. C. Carr, A. F. Ayyobi, and J. D. Brunzell Hepatic lipase and dyslipidemia: interactions among genetic variants, obesity, gender, and diet J. Lipid Res., July 1, 2003; 44(7): 1279 - 1286. [Abstract] [Full Text] [PDF]

				Y. Ando, T. Shimizugawa, S. Takeshita, M. Ono, M. Shimamura, R. Koishi, and H. Furukawa A decreased expression of angiopoietin-like 3 is protective against atherosclerosis in apoE-deficient mice J. Lipid Res., June 1, 2003; 44(6): 1216 - 1223. [Abstract] [Full Text] [PDF]

				L. C. Wilsie and R. A. Orlando The Low Density Lipoprotein Receptor-related Protein Complexes with Cell Surface Heparan Sulfate Proteoglycans to Regulate Proteoglycan-mediated Lipoprotein Catabolism J. Biol. Chem., April 25, 2003; 278(18): 15758 - 15764. [Abstract] [Full Text] [PDF]

				A. Kawakami, A. Tanaka, K. Nakajima, K. Shimokado, and M. Yoshida Atorvastatin Attenuates Remnant Lipoprotein-Induced Monocyte Adhesion to Vascular Endothelium Under Flow Conditions Circ. Res., August 9, 2002; 91(3): 263 - 271. [Abstract] [Full Text] [PDF]

				J. E. Hokanson, S. Cheng, J. K. Snell-Bergeon, B. A. Fijal, M. A. Grow, C. Hung, H. A. Erlich, J. Ehrlich, R. H. Eckel, and M. Rewers A Common Promoter Polymorphism in the Hepatic Lipase Gene (LIPC-480C>T) Is Associated With an Increase in Coronary Calcification in Type 1 Diabetes Diabetes, April 1, 2002; 51(4): 1208 - 1213. [Abstract] [Full Text] [PDF]

				R. Abia, Y. M. Pacheco, J. S. Perona, E. Montero, F. J. G. Muriana, and V. Ruiz-Gutiérrez The Metabolic Availability of Dietary Triacylglycerols from Two High Oleic Oils during the Postprandial Period Does Not Depend on the Amount of Oleic Acid Ingested by Healthy Men J. Nutr., January 1, 2001; 131(1): 59 - 65. [Abstract] [Full Text]

				A. Zambon, S. S. Deeb, A. Bensadoun, K. E. Foster, and J. D. Brunzell In vivo evidence of a role for hepatic lipase in human apoB-containing lipoprotein metabolism, independent of its lipolytic activity J. Lipid Res., December 1, 2000; 41(12): 2094 - 2099. [Abstract] [Full Text]

				C. Desurmont, J.-M. Caillaud, F. Emmanuel, P. Benoit, J. C. Fruchart, G. Castro, D. Branellec, J.-M. Heard, and N. Duverger Complete Atherosclerosis Regression After Human ApoE Gene Transfer in ApoE-Deficient/Nude Mice Arterioscler. Thromb. Vasc. Biol., February 1, 2000; 20(2): 435 - 442. [Abstract] [Full Text] [PDF]

				Y. Kako, L.-S. Huang, J. Yang, T. Katopodis, R. Ramakrishnan, and I. J. Goldberg Streptozotocin-induced diabetes in human apolipoprotein B transgenic mice: effects on lipoproteins and atherosclerosis J. Lipid Res., December 1, 1999; 40(12): 2185 - 2194. [Abstract] [Full Text] [PDF]

				S.-Q. Xiang, K. Cianflone, D. Kalant, and A. D. Sniderman Differential binding of triglyceride-rich lipoproteins to lipoprotein lipase J. Lipid Res., September 1, 1999; 40(9): 1655 - 1663. [Abstract] [Full Text]

				R. W. Mahley and Z.-S. Ji Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E J. Lipid Res., January 1, 1999; 40(1): 1 - 16. [Abstract] [Full Text]

				F. Karpe, T. Olivecrona, G. Olivecrona, J. S. Samra, L. K. M. Summers, S. M. Humphreys, and K. N. Frayn Lipoprotein lipase transport in plasma: role of muscle and adipose tissues in regulation of plasma lipoprotein lipase concentrations J. Lipid Res., December 1, 1998; 39(12): 2387 - 2393. [Abstract] [Full Text]